This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prince, G. A.
Right arrow Articles by Porter, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prince, G. A.
Right arrow Articles by Porter, D. D.

 Previous Article  |  Next Article 

Journal of Virology, November 2000, p. 10287-10292, Vol. 74, No. 22
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Efficacy and Safety Studies of a Recombinant Chimeric Respiratory Syncytial Virus FG Glycoprotein Vaccine in Cotton Rats

Gregory A. Prince,1,* Carine Capiau,2 Marguerite Deschamps,2 Luc Fabry,2 Nathalie Garçon,2 Dirk Gheysen,2 Jean-Paul Prieels,2 Georges Thiry,2 Omer Van Opstal,2 and David D. Porter3

Virion Systems, Inc., Rockville, Maryland 208501; SmithKline Beecham Biologicals s.a., B-1330 Rixensart, Belgium2; and Department of Pathology and Laboratory Medicine, University of California School of Medicine, Los Angeles, California 900953

Received 12 July 2000/Accepted 16 August 2000

Several formulations of a recombinant chimeric respiratory syncytial virus (RSV) vaccine consisting of the extramembrane domains of the F and G glycoproteins (FG) were tested in cotton rats to evaluate efficacy and safety. The FG vaccine was highly immunogenic, providing nearly complete resistance to pulmonary infection at doses as low as 25 ng in spite of inducing relatively low levels of serum neutralizing antibody at low vaccine doses. Upon RSV challenge animals primed with FG vaccine showed quite mild alveolitis and interstitial pneumonitis, which were eliminated by the addition of monophosphoryl lipid A to the formulation.

* Corresponding author. Mailing address: Virion Systems, Inc., 9610 Medical Center Dr., Ste. 100, Rockville, MD 20850-3347. Phone: (301) 309-1844. Fax: (301) 309-0471. E-mail: gprince{at}erols.com.

Journal of Virology, November 2000, p. 10287-10292, Vol. 74, No. 22
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hamelin, M.-E., Yim, K., Kuhn, K. H., Cragin, R. P., Boukhvalova, M., Blanco, J. C. G., Prince, G. A., Boivin, G. (2005). Pathogenesis of Human Metapneumovirus Lung Infection in BALB/c Mice and Cotton Rats. J. Virol. 79: 8894-8903 [Abstract] [Full Text]  
  • Prince, G. A., Mond, J. J., Porter, D. D., Yim, K. C., Lan, S. J., Klinman, D. M. (2003). Immunoprotective Activity and Safety of a Respiratory Syncytial Virus Vaccine: Mucosal Delivery of Fusion Glycoprotein with a CpG Oligodeoxynucleotide Adjuvant. J. Virol. 77: 13156-13160 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»